macro

Novo Nordisk adds exploratory CagriSema data on weight loss and daily function

Novo Nordisk released two exploratory REDEFINE 1 analyses of CagriSema showing varied weight-loss paths, better daily activity and more side effects.

the same feed is available to bots and dashboards through the api. connect the api →

what happened

Novo Nordisk has published two more exploratory analyses from the late-stage REDEFINE 1 study of its experimental obesity drug CagriSema, according to Seeking Alpha. The company reports that adults with obesity who took the treatment followed different weight-loss curves and reported easier everyday physical activity.

Among those analyzed, 67.8% shed at least 5% of body weight within eight weeks. Faster responders averaged 25.4% weight loss by week 68, while slower responders averaged 17.8%. Novo stresses that these figures were gathered during treatment and should not be used to alter clinical decisions.

why it matters

Investors will watch whether the extra data strengthen the case for CagriSema before the US regulatory decision Novo expects in the fourth quarter of 2026. A questionnaire found 73.1% of patients noticed meaningful gains in physical activity versus 49.1% on placebo, but digestive side effects hit 79.6% against 39.9%, and discontinuation for that reason ran 5.9% versus 3.5%. CagriSema remains unapproved in the United States.

market impact

Novo Nordisk shares: efficacy data support sentiment, but higher side-effect rates temper the upside

  • Novo Nordisk shares mixed — stronger efficacy signals are offset by weaker tolerability data

tags

instruments

Novo Nordisk sharesCagriSemaNovo Nordisk

sources

  1. Novo Nordisk reports additional CagriSema weight-loss findings — Seeking Alpha, 15 November 2026 at 20:09 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗